ArticleEmerging infectious diseases2015
Uncommon Candida Species Fungemia among Cancer Patients, Houston, Texas, USA.
Article in Emerging infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- Clinical outcomes of antimicrobial resistance in cancer patients: a systematic review of multivariable models.BMC infectious diseases · 2023Pooled it
- Clinical Characteristics and Mortality Risk Factors ofAnnals of laboratory medicine · 2026Article
- Article
- Carvacrol Reduces Virulence Traits inMicroorganisms · 2026Article
- Encephalopathy and Endophthalmitis Following Device-Related InvasiveClinical case reports · 2025Article
- Article
- Article
- Identification of Virulence Factors in Isolates ofMicroorganisms · 2024Article
- Diagnosis and Treatment Challenges ofCase reports in infectious diseases · 2024Article
- Emergence of cryptic species and clades ofMicrobiology spectrum · 2023Article
- Alarming Increase of Azole-Resistant Candida Causing Blood Stream Infections in Oncology Patients in Egypt.Current microbiology · 2023Article
- Molecular Characterization and Sterol Profiles Identify Nonsynonymous Mutations inMicrobiology spectrum · 2023Article
- Candida lusitaniae, an Emerging Opportunistic Pathogen in Immunocompetent Populations: A Case Report.Cureus · 2023Article
- Candida haemulonii complex, an emerging threat from tropical regions?PLoS neglected tropical diseases · 2023Review
- Article
- Review
- Increasing Gram-Negative Catheter-Related Bloodstream Infection in Cancer Patients.Pathogens (Basel, Switzerland) · 2023Article
- Invasive Candida kefyr infection presenting as pyelonephritis in an ICU hospitalized COVID-19 patient: Case report and review of the literature.Journal de mycologie medicale · 2022Review
- Review
- Etest ECVs/ECOFFs for Detection of Resistance in Prevalent and Three NonprevalentAntimicrobial agents and chemotherapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many uncommon Candida species that cause bloodstream infections (BSIs) are not well-characterized. We investigated the epidemiology, antifungal use, susceptibility patterns, and factors associated with all-cause death among cancer patients in whom uncommon Candida spp. BSIs were diagnosed at a cancer treatment center during January 1998–September 2013. Of 1,395 Candida bloodstream isolates, 79 from 68 patients were uncommon Candida spp. The incidence density of uncommon Candida spp. BSIs and their proportion to all candidemia episodes substantively increased during the study period, and the rise was associated with increasing use of echinocandin antifungal drugs. Thirty-seven patients had breakthrough infections during therapy or prophylaxis with various systemic antifungal drugs for >7 consecutive days; 21 were receiving an echinocandin. C. kefyr (82%), and C. lusitaniae (21%) isolates frequently showed caspofungin MICs above the epidemiologic cutoff values. These findings support the need for institutional surveillance for uncommon Candida spp. among cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.